Teva Pharmaceutical Expects 2024 Revenues Of $16.0B-$16.4B Versus Prior Guidance Of $15.7B-$16.3B And Consensus Of $16.012B
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceutical has updated its 2024 revenue guidance to $16.0B-$16.4B, up from the previous $15.7B-$16.3B and above the consensus of $16.012B. Key product revenue projections have also been adjusted, with AUSTEDO expected to generate ~$1,600M, up from ~$1,500M, and COPAXONE expected to generate ~$450M, up from ~$400M. Other financial metrics such as operating income, adjusted EBITDA, and diluted EPS have seen slight improvements.
July 31, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Teva Pharmaceutical has raised its 2024 revenue guidance to $16.0B-$16.4B, up from the previous $15.7B-$16.3B and above the consensus of $16.012B. Key product revenue projections for AUSTEDO and COPAXONE have also been increased. This positive outlook is likely to boost investor confidence and support short-term stock price appreciation.
The increase in revenue guidance and key product revenue projections indicates a stronger financial outlook for Teva Pharmaceutical. This is likely to positively impact investor sentiment and support short-term stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100